Cross-talk between oncogene-driven signaling pathways and thyroid cancer metabolism

癌基因驱动的信号通路与甲状腺癌代谢之间的串扰

基本信息

项目摘要

Background: The next-generation sequencing led to the categorization of thyroid cancer (TC) into BRAF-like and RAS-like tumors. The BRAF-RAS score (BRS) was developed to quantify the extent to which the gene expression profile resembles either the BRAFV600E- or RAS-mutant profiles and is utilized as a continuous measure from -1 to +1, respectively. Oncogene-driven signaling pathways have an impact on intracellular metabolismglycolysis and oxidative phosphorylation (OXPHOS). There are limited data on the genotype-metabolic phenotype correlation in TC. Therefore, the goal of this study was to perform a comprehensive analysis of the association between BRS and TC metabolism. Methods: We analyzed mRNA expression of key enzymes involved in glycolysis and OXPHOS in 496 BRAF-like and RAS-like human TC tissue samples based on The Cancer Genome Atlas. We performed an in vitro study using 6 TC cell lines 4 BRAF-like, and 2 RAS-like. OXPHOS was determined by measuring oxygen consumption rate (OCR), while glycolysis was measured using the extracellular acidification rate (ECAR), utilizing the Seahorse XF analyzer. The association between the OCR, ECAR, and BRS was tested using the Pearson correlation coefficient r. Results: RAS-like tumors were associated with higher mRNA expression of OXPHOS-related genes, as documented by a low-to-moderate positive correlation between its mRNA expression and BRS - r ranging from 0.28, p<0.001 for SDHB to 0.54, p<0.001 for cytochrome bc1 complex. BRAF-like tumors were characterized by a higher expression of glycolytic enzymes as evidenced by a low-to-strong negative correlation between its mRNA expression and BRS - r ranging from -0.2 for hexokinase II to -0.65 for pyruvate kinase. Consistently, RAS-like cell lines were utilizing OXPHOS and glycolysis for energy production, while BRAF-like cell lines were characterized by a glycolytic phenotype and low OXPHOS rate. There was a strong positive correlation between the BRS and OCR (r=0.79, p=0.03) and no correlation between BRS and ECAR (r=-0.12, p=0.82). Conclusions: BRAF-like and RAS-like tumors are characterized by a distinct metabolic phenotype, with RAS-like tumors relying more on OXPHOS than BRAF-like cells. Therapeutic strategies targeting oncogene-driven signaling pathways and distinct cancer metabolism are necessary for the individualized approach to TC therapy.
背景:下一代测序导致甲状腺癌(TC)分为BRAF样和RAS样肿瘤。开发BRAF-RAS评分(BRS)以定量基因表达谱与BRAFV 600 E-或RAS-突变谱相似的程度,并分别用作-1至+1的连续测量。癌基因驱动的信号通路对细胞内代谢有影响,如糖酵解和氧化磷酸化(OXPHOS)。关于TC的基因型-代谢表型相关性的数据有限。因此,本研究的目的是对BRS和TC代谢之间的关联进行全面分析。 研究方法:我们基于癌症基因组图谱分析了496例BRAF样和RAS样人TC组织样本中参与糖酵解和OXPHOS的关键酶的mRNA表达。我们使用6个TC细胞系4个BRAF样和2个RAS样进行了体外研究。OXPHOS通过测量氧消耗速率(OCR)来确定,而糖酵解使用细胞外酸化速率(ECAR)来测量,使用Seahorse XF分析仪。使用Pearson相关系数r检验OCR、ECAR和BRS之间的关联。 结果如下:RAS样肿瘤与OXPHOS相关基因的较高mRNA表达相关,如其mRNA表达与BRS - r之间的低至中度正相关性所证明的,范围从SDHB的0.28,p<0.001到细胞色素bc 1复合物的0.54,p<0.001。BRAF样肿瘤的特征在于糖酵解酶的更高表达,如其mRNA表达与BRS-r之间的低至强负相关性所证明的,BRS-r范围从己糖激酶II的-0.2至丙酮酸激酶的-0.65。同样,RAS样细胞系利用OXPHOS和糖酵解产生能量,而BRAF样细胞系的特征在于糖酵解表型和低OXPHOS率。BRS与OCR之间存在强正相关性(r=0.79,p=0.03),而BRS与ECAR之间无相关性(r=-0.12,p=0.82)。 结论:BRAF样和RAS样肿瘤的特征在于不同的代谢表型,RAS样肿瘤比BRAF样细胞更依赖OXPHOS。针对癌基因驱动的信号通路和不同的癌症代谢的治疗策略是必要的TC治疗的个性化方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Joanna Klubo-Gwiezdzinska其他文献

Joanna Klubo-Gwiezdzinska的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Joanna Klubo-Gwiezdzinska', 18)}}的其他基金

Somatostatin receptors in the diagnosis and treatment of thyroid cancer
生长抑素受体在甲状腺癌诊断和治疗中的作用
  • 批准号:
    10700681
  • 财政年份:
  • 资助金额:
    $ 49.6万
  • 项目类别:
Use of metformin in the treatment of thyroid cancer
二甲双胍在治疗甲状腺癌中的用途
  • 批准号:
    10011331
  • 财政年份:
  • 资助金额:
    $ 49.6万
  • 项目类别:
Studies of Thyroid Function in Health and Disease
健康和疾病中的甲状腺功能研究
  • 批准号:
    10011456
  • 财政年份:
  • 资助金额:
    $ 49.6万
  • 项目类别:
Somatostatin receptors in the diagnosis and treatment of thyroid cancer
生长抑素受体在甲状腺癌诊断和治疗中的作用
  • 批准号:
    9553303
  • 财政年份:
  • 资助金额:
    $ 49.6万
  • 项目类别:
Cross-talk between oncogene-driven signaling pathways and thyroid cancer metabolism
癌基因驱动的信号通路与甲状腺癌代谢之间的串扰
  • 批准号:
    10931300
  • 财政年份:
  • 资助金额:
    $ 49.6万
  • 项目类别:
Application of molecular diagnostics in thyroid cancer
分子诊断在甲状腺癌中的应用
  • 批准号:
    10255253
  • 财政年份:
  • 资助金额:
    $ 49.6万
  • 项目类别:
Studies of Benign and Malignant Thyroid Disease
良性和恶性甲状腺疾病的研究
  • 批准号:
    10700666
  • 财政年份:
  • 资助金额:
    $ 49.6万
  • 项目类别:
Studies of Thyroid Function in Health and Disease
健康和疾病中的甲状腺功能研究
  • 批准号:
    10706218
  • 财政年份:
  • 资助金额:
    $ 49.6万
  • 项目类别:
Studies of Thyroid Function in Health and Disease
健康和疾病中的甲状腺功能研究
  • 批准号:
    10255335
  • 财政年份:
  • 资助金额:
    $ 49.6万
  • 项目类别:
Somatostatin receptors in the diagnosis and treatment of thyroid cancer
生长抑素受体在甲状腺癌诊断和治疗中的作用
  • 批准号:
    10011325
  • 财政年份:
  • 资助金额:
    $ 49.6万
  • 项目类别:

相似海外基金

Drug resistance and calcium signaling in cancer cell line
癌细胞系中的耐药性和钙信号传导
  • 批准号:
    20K16338
  • 财政年份:
    2020
  • 资助金额:
    $ 49.6万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Identification of novel target molecules involved in spontaneous bone metastasis of mouse breast cancer cell line.
鉴定参与小鼠乳腺癌细胞系自发骨转移的新靶分子。
  • 批准号:
    17K07159
  • 财政年份:
    2017
  • 资助金额:
    $ 49.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Differential expression of cell adhesion molecule of CD133-positive / negative cells derived from oral cancer cell line and diagnostic treatment targeting it
口腔癌细胞系CD133阳性/阴性细胞细胞粘附分子的差异表达及针对其的诊断治疗
  • 批准号:
    17K17251
  • 财政年份:
    2017
  • 资助金额:
    $ 49.6万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Two types of monoclonal antibodies generated by immunizing mice with MIA-PaCa-2 human pancreatic cancer cell line for diagnostic and therapeutic strategies for pancreatic cancer
用 MIA-PaCa-2 人胰腺癌细胞系免疫小鼠产生两种类型的单克隆抗体,用于胰腺癌的诊断和治疗策略
  • 批准号:
    16K10595
  • 财政年份:
    2016
  • 资助金额:
    $ 49.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Metabolome analysis of invaded pancreatic cancer cell line, PANC-1, after irradiation
照射后侵袭性胰腺癌细胞系 PANC-1 的代谢组分析
  • 批准号:
    25461934
  • 财政年份:
    2013
  • 资助金额:
    $ 49.6万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Proteomics analysis of cancer stem cell and its microenvironment using FFPE tissue and cancer cell line
使用 FFPE 组织和癌细胞系对癌症干细胞及其微环境进行蛋白质组学分析
  • 批准号:
    25710013
  • 财政年份:
    2013
  • 资助金额:
    $ 49.6万
  • 项目类别:
    Grant-in-Aid for Young Scientists (A)
Autophagy is involved in a clearance of anti-cancer agent doxorubicin in the multidrug resistant cancer cell line.
自噬参与多药耐药癌细胞系中抗癌药物阿霉素的清除。
  • 批准号:
    25670083
  • 财政年份:
    2013
  • 资助金额:
    $ 49.6万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
An attempt to identify new antigens recognized by tumor-specific cytotoxic T lymphocytes using a HLA-modified ovarian cancer cell line as an artificial antigen presenting cell
尝试使用 HLA 修饰的卵巢癌细胞系作为人工抗原呈递细胞来鉴定肿瘤特异性细胞毒性 T 淋巴细胞识别的新抗原
  • 批准号:
    24659727
  • 财政年份:
    2012
  • 资助金额:
    $ 49.6万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Studies on the epigenetic mechanism of arsenic carcinogenesis on human liver cancer cell line
砷致癌人肝癌细胞系的表观遗传机制研究
  • 批准号:
    23790680
  • 财政年份:
    2011
  • 资助金额:
    $ 49.6万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Supramolecular Assembly of Amphiphilic Mesogenic Compounds InducingApoptosis in a Human Solid Cancer Cell Line
诱导人实体癌细胞系凋亡的两亲性介晶化合物的超分子组装
  • 批准号:
    23651229
  • 财政年份:
    2011
  • 资助金额:
    $ 49.6万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了